Figure 2 from First-in-Human Phase I/II Study of INCAGN01876, a Glucocorticoid-Induced Tumor Necrosis Factor Receptor Agonist, in Patients with Advanced or Metastatic Solid Tumors

Figure 2 from First-in-Human Phase I/II Study of INCAGN01876, a Glucocorticoid-Induced Tumor Necrosis Factor Receptor Agonist, in Patients with Advanced or Metastatic Solid Tumors

<p><b>A,</b> INCAGN01876 mean (±SE) concentration–time profiles after the first dose and at steady state. <b>B,</b> Relationship between serum concentrations of INCAGN01876 and GITR receptor occupancy. <b>C,</b> Percentage of INCAGN01876 receptor occupancy v...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autore principale: Omid Hamid (15023912) (author)
Altri autori: Dana B. Cardin (15023858) (author), F. Stephen Hodi (15131927) (author), Patricia LoRusso (15134565) (author), Taha Merghoub (15032538) (author), Roberta Zappasodi (15043913) (author), Rachana Maniyar (22348811) (author), John E. Janik (22348814) (author), Maikel V.W. van der Velden (22348817) (author), Feng Zhou (22348820) (author), Zhiwan Dong (22348823) (author), Xuejun Chen (22348826) (author), James J. Harding (15032705) (author)
Pubblicazione: 2025
Soggetti:
Cancer
Immuno-oncology
Clinical Research and Trials
Clinical Trial Results
Phase I clinical trials
Immunology
Antibodies/immunoconjugates
Cytokines
Regulatory T cells
T cell exhaustion
Immunotherapy
Agonist antibodies
Checkpoint blockade
Toxicities/irAEs
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi